ALIVUS1,390.00

Alivus Life Sciences Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersDIVISLABAARTIDRUGSAKUMSAGARWALEYEAPLLTDADVENZYMESAARTIPHARMCORONA
View
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Last 12M
30/06/2026
Revenue from Operations2,123.22,161.22,283.22,590.4
Other Income14.729.073.8
Total Income2,137.92,190.22,295.32,664.2
Expenses
+ Cost of Materials Consumed1,001.61,098.51,058.61,047.2
+ Changes in Inventories41.3-84.4-56.64.1
+ Employee Benefit Expense168.7180.2258.2279.1
+ Finance Costs28.00.51.55.4
+ Depreciation & Amortisation37.942.153.578.9
+ Other Expenses295.5324.7423.3
Total Expenses1,573.01,561.61,664.01,838.0
EBITDA616.1642.3674.2836.7
EBIT578.2600.2620.8757.8
Profit
PBT before Exceptional Items826.2
+ Exceptional Items-25.7
Pretax Income564.9628.6631.3800.6
+ Current Tax137.6150.6152.2195.2
+ Deferred Tax8.611.08.22.3
Tax Expense146.2161.6160.4197.5
Net Income418.7467.0470.9603.0
+ Net Income — Continuing Ops603.0
+ Other Comprehensive Income1.8
Total Comprehensive Income418.8466.7465.4604.9
Per Share
Basic EPS35.6338.1149.12
Diluted EPS35.6338.1149.03
Other Comprehensive Income — detail
+ Other Comprehensive Income1.8
+ Items NOT to be Reclassified to P&L2.5
+ Tax on Items NOT to be Reclassified0.6
Per Share — as-filed variants
Basic EPS — Continuing Operations49.12
Diluted EPS — Continuing Operations49.03
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,080.31,147.11,281.21,539.2
Gross Margin %50.8853.0856.1159.42
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)826.2
− Exceptional Items (reconciliation)-25.7
Net Income Adj (tax-effected)622.4
EPS Adj50.69
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.00
Paid Up Equity Capital24.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.